Hypoxia-inducible factor in cancer
DOI:
https://doi.org/10.24265/horizmed.2023.v23n4.11Keywords:
hypoxia-inducible factor-proline dioxygenases, Von Hippel-Lindau tumor suppressor protein, hypoxia-inducible factor 1, neoplasmsAbstract
Oxygen and carbon dioxide are essential for breathing; variations in these gases outside of the normal range are a threat to cell survival. Hypoxia is a common condition that occurs in most malignant tumors, increases angiogenesis and defective
vascularization, promotes cell proliferation and acquires an epithelial–mesenchymal transition phenotype, which causes metastasis. It also affects cancer cell metabolism and makes patients resistant to treatment by causing cell quiescence.
As a result, hypoxia is a detrimental component that is linked to unfavorable outcomes in most cancer treatments. Through the activation of more than a hundred genes that control cell activity, which produce key functions for cancer development, the transcription factor known as hypoxia-inducible factor (HIF) is linked to hypoxia in cancer. This review’s main goals are to highlight the role of hypoxia in the development of cancer, identify the key molecules that interact to promote HIF expression, explain the molecular mechanisms of the pathways that lead to HIF induction, describe the
cellular effects of HIF alteration, and discuss potential HIF-targeted therapies. Articles from 1990 to 2022 were reviewed in PubMed, Scopus and SciELO databases. Keywords related to cancer and HIF were searched in bibliographical references.
In conclusion, HIF-1α overexpression in tumor biopsies is associated with increased patient mortality in human cancers. Potential HIF-1α-regulated target genes that may play a role in tumor progression are starting to be identified. Although
hundreds of chemicals have been studied in relation to HIF in cancer, there are currently few approved HIF inhibitors available on the global market; moreover, many clinical trials, in their various stages of development, do not show encouraging results. It is likely that in the future, when there is a better understanding of the structure, molecular and biological functioning of this factor, more specific drugs for HIF inhibition will be developed.
Downloads
References
Cummins EP, Strowitzki MJ, Taylor CT. Mechanisms and consequences of oxygen and carbon dioxide sensing in mammals. Physiol Rev. 2020;100(1):463-88.
Cogliati S, Cabrera-Alarcon JL, Enriquez JA. Regulation and functional role of the electron transport chain supercomplexes. Biochem Soc Trans. 2021;49(6):2655-68.
Kim LC, Simon MC. Hypoxia-inducible factors in cancer. Cancer Res. 2022;82(2):195-6.
Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999;59(22):5830-5.
Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 2015;3:83-92.
Hompland T, Fjeldbo CS, Lyng H. Tumor hypoxia as a barrier in cancer therapy: Why levels matter. Cancers (Basel). 2021;13(3):499.
Lee P, Chandel NS, Simon MC. Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. Nat Rev Mol Cell Biol. 2020;21(5):268-83.
Kolonko M, Greb-Markiewicz B. bHLH-PAS Proteins: Their structure and intrinsic disorder. Int J Mol Sci. 2019;20(15):3653.
Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995;92(12):5510-4.
Keith B, Johnson RS, Simon MC. HIF1a and HIF2a: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2011;12(1):9-22.
Torii S, Sakaki K, Otomo M, Saka K, Yasumoto K, Sogawa K. Nucleocytoplasmic shuttling of IPAS by its unique nuclear import and export signals unshared with other HIF-3a splice variants. J Biochem. 2013;154(6):561-7.
Yamashita K, Discher DJ, Hu J, Bishopric NH, Webster KA. Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, AND p300/ CBP. J Biol Chem. 2001;276(16):12645-53.
Kaelin WGJ. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer. 2008;8(11):865-73.
Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxiainducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271-5.
Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol. 2006;70(5):1469-80.
Semenza GL. Regulation of mammalian O2 homeostasis by hypoxiainducible factor 1. Annu Rev Cell Dev Biol. 1999;15:551-78.
Dann CE3, Bruick RK, Deisenhofer J. Structure of factor-inhibiting hypoxia-inducible factor 1: An asparaginyl hydroxylase involved in the hypoxic response pathway. Proc Natl Acad Sci U S A. 2002;99(24):15351-6.
Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci U S A. 2011;108(10):4129-34.
Agani F, Jiang B. Oxygen-independent regulation of HIF-1: novel involvement of PI3K/AKT/mTOR pathway in cancer. Curr Cancer Drug Targets. 2013;13(3):245-51.
Carrera S, Senra J, Acosta MI, Althubiti M, Hammond EM, de Verdier PJ, et al. The role of the HIF-1a transcription factor in increased cell division at physiological oxygen tensions. PLoS One. 2014;9(5):e97938.
Lau CK, Yang ZF, Ho DW, Ng MN, Yeoh GC, Poon RT, et al. An Akt/ hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. Clin Cancer Res. 2009;15(10):3462-71.
Biswas S, Mukherjee R, Tapryal N, Singh AK, Mukhopadhyay CK. Insulin regulates hypoxia-inducible factor-1a transcription by reactive oxygen species sensitive activation of Sp1 in 3T3-L1 preadipocyte. PLoS One. 2013;8(4):e62128.
Sinha S, Koul N, Dixit D, Sharma V, Sen E. IGF-1 induced HIF-1a-TLR9 cross talk regulates inflammatory responses in glioma. Cell Signal. 2011;23(11):1869-75.
Hubbi ME, Semenza GL. Regulation of cell proliferation by hypoxiainducible factors. Am J Physiol Cell Physiol. 2015;309(12):C775-82.
Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012;33(4):207-14.
Kumar H, Choi D. Hypoxia inducible factor pathway and physiological adaptation: A cell survival pathway? Mediators Inflamm. 2015;2015:584758.
Greijer AE, van der Wall E. The role of hypoxia inducible factor 1 (HIF-in hypoxia induced apoptosis. J Clin Pathol. 2004;57(10):1009-14.
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-6.
Hickey MM, Simon MC. Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Curr Top Dev Biol. 2006;76:217-57.
Prager GW, Poettler M, Unseld M, Zielinski CC. Angiogenesis in cancer: Anti-VEGF escape mechanisms. Transl Lung Cancer Res. 2012;1(1):14-25.
Otto AM. Warburg effect(s)-a biographical sketch of Otto Warburg and his impacts on tumor metabolism. Cancer Metab. 2016;4:5.
Sharma A, Sinha S, Shrivastava N. Therapeutic targeting hypoxiainducible factor (HIF-1) in cancer: Cutting gordian knot of cancer cell metabolism. Front Genet. 2022;13:849040.
Semenza GL. Regulation of metabolism by hypoxia-inducible factor 1. Cold Spring Harb Symp Quant Biol. 2011;76:347-53.
He G, Jiang Y, Zhang B, Wu G. The effect of HIF-1a on glucose metabolism, growth and apoptosis of pancreatic cancerous cells. Asia Pac J Clin Nutr. 2014;23(1):174-80.
Parks SK, Chiche J, Pouyssegur J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer. 2013;13(9):611-23.
Dang CV, Kim J, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer. 2008;8(1):51-6.
Araos J, Sleeman JP, Garvalov BK. The role of hypoxic signalling in metastasis: towards translating knowledge of basic biology into novel anti-tumour strategies. Clin Exp Metastasis. 2018;35(7):563-99.
Zhang S, Zhou X, Wang B, Zhang K, Liu S, Yue K, et al. Loss of VHL expression contributes to epithelial-mesenchymal transition in oral squamous cell carcinoma. Oral Oncol. 2014;50(9):809-17.
Wong CC, Gilkes DM, Zhang H, Chen J, Wei H, Chaturvedi P, et al. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci U S A. 2011;108(39):16369-74.
Zhang Q, Han Z, Zhu Y, Chen J, Li W. Role of hypoxia inducible factor-1 in cancer stem cells (Review). Mol Med Rep. 2021;23(1):17.
Ghosh R, Samanta P, Sarkar R, Biswas S, Saha P, Hajra S, et al. Targeting HIF-1a by natural and synthetic compounds: A promising approach for anti-cancer therapeutics development. Molecules. 2022;27(16):5192.
Semenza GL. Pharmacologic targeting of hypoxia-inducible factors. Annu Rev Pharmacol Toxicol. 2019;59:379-403.
Newman RA, Yang P, Pawlus AD, Block KI. Cardiac glycosides as novel cancer therapeutic agents. Mol Interv. 2008;8(1):36-49.
White PT, Subramanian C, Zhu Q, Zhang H, Zhao H, Gallagher R, et al. Novel HSP90 inhibitors effectively target functions of thyroid cancer stem cell preventing migration and invasion. Surgery. 2016;159(1):142-51.
Lock FE, McDonald PC, Lou Y, Serrano I, Chafe SC, Ostlund C, et al. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene. 2013;32(44):5210-9.
Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther. 2004;3(3):233-44.
Palayoor ST, Mitchell JB, Cerna D, Degraff W, John-Aryankalayil M, Coleman CN. PX-478, an inhibitor of hypoxia-inducible factor1alpha, enhances radiosensitivity of prostate carcinoma cells. Int J Cancer. 2008;123(10):2430-7.
National Center for Biotechnology Information. PubChem Compound Summary for CID 6505803, Tanespimycin [Internet]. National Library of Medicine. 2023 [citado el 21 de mayo de 2023]. Disponible en: https://pubchem.ncbi.nlm.nih.gov/compound/6505803
Huang Z, Wu Y, Zhou X, Xu J, Zhu W, Shu Y, et al. Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials. Future Oncol. 2014;10(10):1795-807.
Sharma A, Preuss CV. Bortezomib. En: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
Fallah J, Brave MH, Weinstock C, Mehta GU, Bradford D, Gittleman H, et al. FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors. Clin Cancer Res. 2022;28(22):4843-48.
Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, et al. Belzutifan for renal cell carcinoma in von HippelLindau disease. N Engl J Med. 2021;385(22):2036-46.
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Franklin Aldecoa Bedoya
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
